Presumptive implications of epidermal growth factors in inflammation
Keywords:
serum biomarkers/inflammation, epidermal growth factor, CIMAvax-EGFAbstract
Epidermal Growth Factor is a protein of only 53 amino acids, with considerable thermodynamic stability, provided by its three desulfide bridges. It has structural homology with a wide series of growth factors, distinguishing its typical motif from this family of proteins. The known function of this molecule is closely related to the heterodimerization of ErbB1 and its activation with implications in cell metabolism and cell division. Although the role of EGFR is well documented in the inflammatory context, information regarding the participation of its ligand is scarce. Evidence suggests that this molecule could be a promising marker of inflammation. A better understanding of the role of EGF in inflammation opens new therapeutic opportunities in the Cuban scenario based on the positioning of CIMAvax-EGF, a serum EGF depletion therapy with consolidated safety.
Downloads
References
Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem [Internet]. 1987 [cited 2023 Nov 30];56(1):881–914. Available from: https://pubmed.ncbi.nlm.nih.gov/3039909/
Shakhakarmi K, Seo JE, Lamichhane S, Thapa C, Lee S. EGF, a veteran of wound healing: highlights on its mode of action, clinical applications with focus on wound treatment, and recent drug delivery strategies. Arch Pharm Res [Internet]. 2023 [cited 2023 Nov 30];46(4):299–322. Available from: https://pubmed.ncbi.nlm.nih.gov/36928481/
Gray A, Dull TJ, Ullrich A. Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor. Nature [Internet]. 1983 [cited 2023 Nov 30];303(5919):722–5. Available from: https://pubmed.ncbi.nlm.nih.gov/6304537/
Bell GI, Fong NM, Stempien MM, Wormsted MA, Caput D, Ku L, et al. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res [Internet]. 1986 [cited 2023 Nov 30];14(21):8427–46. Available from: https://pubmed.ncbi.nlm.nih.gov/3491360/
Scott J, Patterson S, Rall L, Bell GI, Crawford R, Penschow J, et al. The structure and biosynthesis of epidermal growth factor precursor. J Cell Sci [Internet]. 1985 [cited 2023 Nov 30];1985(Supplement_3):19–28. Available from: https://pubmed.ncbi.nlm.nih.gov/3011823/
Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res [Internet]. 2017 [cited 2023 Nov 30];143:142–50. Available from: http://dx.doi.org/10.1016/j.antiviral.2017.03.022
Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res [Internet]. 2019 [cited 2023 Nov 30];139:395–411. Available from: https://pubmed.ncbi.nlm.nih.gov/30500458/
Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10aed. Madrid: Elsevier; 2021.
Yoo J, Perez CER, Nie W, Edwards RA, Sinnett-Smith J, Rozengurt E. TNF-α induces upregulation of EGFR expression and signaling in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol [Internet]. 2012 [cited 2023 Nov 30];302(8):G805–14. Available from: https://pubmed.ncbi.nlm.nih.gov/22301110/
Yoo J, Rodriguez Perez CE, Nie W, Sinnett-Smith J, Rozengurt E. TNF-α and LPA promote synergistic expression of COX-2 in human colonic myofibroblasts: role of LPA-mediated transactivation of upregulated EGFR. BMC Gastroenterol [Internet]. 2013 [cited 2023 Nov 30];13(1). Available from: https://pubmed.ncbi.nlm.nih.gov/23688423/
Zhuang S, Liu N. EGFR signaling in renal fibrosis. Kidney Int Suppl (2011) [Internet]. 2014 [cited 2023 Nov 30];4(1):70–4. Available from: https://pubmed.ncbi.nlm.nih.gov/26312153/
Upagupta C, Shimbori C, Alsilmi R, Kolb M. Matrix abnormalities in pulmonary fibrosis. Eur Respir Rev [Internet]. 2018 [cited 2023 Nov 30];27(148):180033. Available from: https://pubmed.ncbi.nlm.nih.gov/29950306/
Kalinina O, Golovkin A, Zaikova E, Aquino A, Bezrukikh V, Melnik O, et al. Cytokine storm signature in patients with moderate and severe COVID-19. Int J Mol Sci [Internet]. 2022 [cited 2023 Nov 30];23(16):8879. Available from: https://pubmed.ncbi.nlm.nih.gov/36012146/
Ahern DJ, Ai Z, Ainsworth M, Allan C, Allcock A, Angus B, et al. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell [Internet]. 2022 [cited 2023 Nov 30];185(5):916-938.e58. Available from: https://pubmed.ncbi.nlm.nih.gov/35216673/
Schumacher N, Rose-John S. ADAM17 orchestrates Interleukin-6, TNFα and EGF-R signaling in inflammation and cancer. Biochim Biophys Acta Mol Cell Res [Internet]. 2022 [cited 2023 Nov 30];1869(1):119141. Available from: https://pubmed.ncbi.nlm.nih.gov/34610348/
Monserrat J, Gómez-Lahoz A, Ortega M, Sanz J, Muñoz B, Arévalo-Serrano J, et al. Role of innate and adaptive cytokines in the survival of COVID-19 patients. Int J Mol Sci [Internet]. 2022 [cited 2023 Nov 30];23(18):10344. Available from: https://pubmed.ncbi.nlm.nih.gov/36142255/
Dülger SU, Mutlu N, Ceylan İ, Özhan E. The relationship between lung fibrosis, the epidermal growth factor receptor, and disease outcomes in COVID-19 pneumonia: a postmortem evaluation. Clin Exp Med [Internet]. 2022;23(4):1181–8. Available from: http://dx.doi.org/10.1007/s10238-022-00872-7
Popa X, García B, Fuentes KP, Huerta V, Alvarez K, Viada CE, et al. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. Oncoimmunology [Internet]. 2020 [cited 2023 Nov 30];9(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32923124/
Crombet Ramos T, Santos Morales O, Dy GK, León Monzón K, Lage Dávila A. The position of EGF deprivation in the management of advanced non-small cell lung cancer. Front Oncol [Internet]. 2021 [cited 2023 Nov 30];11. Available from:https://pubmed.ncbi.nlm.nih.gov/34211836/
RPCEC [Internet]. Havana: Work Team of the Cuban Public Registry of Clinical Trials, National Coordinating Center for Clinical Trials - MINSAP. CIMAvax-EGF®-convalescents with post-COVID-19 respiratory disorders-adults-Phase II (CORVAXCIM); 2021 Dec 06 [cited 2021 Dec 13]; [7 screens]. Available from: https://www.rpcec.sld.cu/ensayos/RPCEC00000375-Sp
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
